ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2011
A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02663934 (Exercise Training to Improve Brain Health in Older HIV+ Individuals), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exercise Training to Improve Brain Health in Older HIV+ Individuals
Who cites it
58 citing papers in PubMed, 97 citations in OpenAlex.
- Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.The Journal of infectious diseases · 2020Trial
- Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy.The Journal of infectious diseases · 2017Trial
- Efavirenz is associated with higher bone mass in South African children with HIV.AIDS (London, England) · 2016Trial
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.BMJ open · 2026Article
- Approaches to optimally target frailty screening among people with HIV in clinical care: findings from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS).Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Frailty-Related Factors among Women Living with and without HIV Aged 40 Years and Older. The Women's Interagency HIV Study.The Journal of frailty & aging · 2024Article
- Review
- Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment.Drug and alcohol dependence · 2022Article
- Prevalence of Frailty and Prefrailty in People With Human Immunodeficiency Virus Aged 50 or Older: A Systematic Review and Meta-Analysis.Open forum infectious diseases · 2022Article
- Frailty Syndrome Is Associated with Poorer Self-Reported Sleep Quality Among Older Persons with Human Immunodeficiency Virus.AIDS research and human retroviruses · 2022Article
- Prevalence of Dyslipidemia in HIV-Positive Women with HPV Coinfection: A Preliminary Study.Scientifica · 2021Article
- Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research.Journal of neurovirology · 2020Review
- Frailty in People Living with HIV.Current HIV/AIDS reports · 2020Review
- Frailty Is an Independent Risk Factor for Mortality, Cardiovascular Disease, Bone Disease, and Diabetes Among Aging Adults With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Observational
- Frailty predicts fractures among women with and at-risk for HIV.AIDS (London, England) · 2019Article
- Global HIV neurology: a comprehensive review.AIDS (London, England) · 2019Review
- Frailty as a predictor of falls in HIV-infected and uninfected women.Antiviral therapy · 2019Article
- Frailty among HIV-1 Infected Adults under Antiretroviral Therapy in Indonesia.Current HIV research · 2019Article
- Ageing with HIV.Healthcare (Basel, Switzerland) · 2018Review
- Inflammation Strikes Again: Frailty and HIV.Current HIV/AIDS reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundIn the general population, frailty, a late stage of the aging process, predicts mortality. We investigated whether manifesting a previously defined frailty-related phenotype (FRP) before initiating highly active antiretroviral therapy (HAART) affects the likelihood of developing clinical AIDS or mortality after HAART initiation.
methodsAmong 596 HIV-infected men in the Multicenter AIDS Cohort Study whose date of HAART initiation was known within ±6 months and who had an assessable FRP status within 3 years before HAART, survival analyses were performed to assess the effect of FRP manifestation on clinical AIDS or death after HAART.
resultsIn men free of AIDS before HAART, AIDS or death after HAART occurred in 13/36 (36%) men who exhibited the FRP before HAART but only in 69/436 (16%) men who did not (hazard ratio = 2.6; 95% confidence interval = 1.4-4.6; p < .01). After adjusting for age, ethnicity, education, nadir CD4+ T-cell count, peak HIV viral load, and hemoglobin in the 3 years before HAART, having the FRP at >25% of visits in the 3 years before HAART significantly predicted AIDS or death (adjusted hazard ratio = 3.8; 95% confidence interval = 1.9-7.9; p < .01). Results were unchanged when the analysis was restricted to the 335 AIDS-free men who were HAART responders, to the 124 men who had AIDS at HAART initiation, or to the subsets of men for whom indices of liver and kidney function could be taken into account.
conclusionHaving a persistent frailty-like phenotype before HAART initiation predicted a worse prognosis after HAART, independent of known risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.